At the time of our work with PowderJect, Dr Paul R. Drayson, Chairman and Chief Executive of PowderJect said:
"We are extremely pleased to continue our long-standing relationship with PA. PA has worked with us for many years now, and PA's strategic investment in PowderJect represents independent validation of the strength of our consumer-focused drug delivery technology. Our new collaboration fits well with our strategy of leveraging external expertise to progress our technology to market, and allows us to benefit from PA's significant experience in industrialising drug delivery devices."
Subsequently, PowderJect was sold to Chiron for £540 million in 2003.
To find out more on our medical device development capabilities please, contact us now.
PRINT
EMAIL
TWITTER
LINKEDIN
FACEBOOK
FEEDS